Wed, October 14, 2009
Tue, October 13, 2009
Mon, October 12, 2009
Fri, October 9, 2009
Thu, October 8, 2009
Wed, October 7, 2009
Tue, October 6, 2009
Mon, October 5, 2009
Sun, October 4, 2009
Fri, October 2, 2009
Thu, October 1, 2009
Wed, September 30, 2009
Tue, September 29, 2009
Mon, September 28, 2009
Fri, September 25, 2009
Thu, September 24, 2009
Wed, September 23, 2009
Tue, September 22, 2009
Mon, September 21, 2009
Fri, September 18, 2009
Thu, September 17, 2009
Wed, September 16, 2009
Tue, September 15, 2009
Mon, September 14, 2009
Fri, September 11, 2009
Thu, September 10, 2009
Wed, September 9, 2009
Tue, September 8, 2009
Sun, September 6, 2009
Fri, September 4, 2009
Thu, September 3, 2009
Wed, September 2, 2009
Tue, September 1, 2009
Mon, August 31, 2009
Fri, August 28, 2009
Thu, August 27, 2009
Wed, August 26, 2009
Tue, August 25, 2009
Mon, August 24, 2009
Sun, August 23, 2009
Fri, August 21, 2009
Thu, August 20, 2009
Wed, August 19, 2009

Eurand N.V.: Eurand to Present at UBS Global Life Sciences Conference


//health-fitness.news-articles.net/content/2009/ .. sent-at-ubs-global-life-sciences-conference.html
Published in Health and Fitness on by Market Wire   Print publication without navigation


PHILADELPHIA, PA--(Marketwire - September 16, 2009) - Eurand N.V. (NASDAQ: [ EURX ]), a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its proprietary pharmaceutical technologies, announced today that John Fraher, Chief Commercial Officer, is scheduled to present at the following conference:

 Event: UBS Global Life Sciences Conference Date: Monday, September 21, 2009 Time: 1:30 p.m. ET Location: Grand Hyatt Hotel New York, N.Y. 

An audio webcast of the Company's presentation will be available by accessing the investor relations section of Eurand's web site at [ www.eurand.com ] and will be available via replay.

About Eurand

Eurand is a specialty pharmaceutical company that develops, manufactures and commercializes enhanced pharmaceutical and biopharmaceutical products based on its proprietary pharmaceutical technologies. Eurand has had six products approved by the FDA since 2001 and has a pipeline of product candidates in development for itself and its collaboration partners. The Company's technology platforms include bioavailability enhancement of poorly soluble drugs, custom release profiles, taste-masking orally disintegrating tablet (ODT) formulations, and drug conjugation.

Eurand is a global company with facilities in the U.S. and Europe. For more information, visit [ www.eurand.com ].


Publication Contributing Sources